CDER now has two deputy directors. And two heads are better than one – especially when they belong to Doug Throckmorton and Bob Temple.
Bob Temple has been named deputy director for clinical science with primary responsibility for high-level initiatives and programs related to clinical science and clinical trial methodology issues. He retains his position as acting director for the office of drug evaluation I.
Current CDER deputy director Dr Douglas Throckmorton becomes deputy director for regulatory programs and will continue as the primary representative on high-level initiatives and programs related to the regulation of drugs that are controlled substances and CDER programs on bioterrorism, emergency response and coordination.
Dr Rachel Behrman has been named acting associate center director for medical policy and acting director of the office of medical policy. She will lead medical policy programs and strategic initiatives involving drug promotion and advertising, clinical trial design, human subject protection and good clinical practices.
A good use of great talent.
Bob Temple has been named deputy director for clinical science with primary responsibility for high-level initiatives and programs related to clinical science and clinical trial methodology issues. He retains his position as acting director for the office of drug evaluation I.
Current CDER deputy director Dr Douglas Throckmorton becomes deputy director for regulatory programs and will continue as the primary representative on high-level initiatives and programs related to the regulation of drugs that are controlled substances and CDER programs on bioterrorism, emergency response and coordination.
Dr Rachel Behrman has been named acting associate center director for medical policy and acting director of the office of medical policy. She will lead medical policy programs and strategic initiatives involving drug promotion and advertising, clinical trial design, human subject protection and good clinical practices.
A good use of great talent.
